Search

Your search keyword '"Yinghui Duan"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Yinghui Duan" Remove constraint Author: "Yinghui Duan"
119 results on '"Yinghui Duan"'

Search Results

1. Deletion of a 1,049 bp sequence from the 5´ UTR upstream of the SiHEC3 gene induces a seed non-shattering mutation in sesame

2. Identification of Fusarium wilt resistance gene SiRLK1 in Sesamum indicum L.

3. Abnormal brain spontaneous neural activity in neuromyelitis optica spectrum disorder with neuropathic pain

4. Generation and characterization of antagonistic anti-human CD39 nanobodies

5. Correlation of GABA+ levels in the medial prefrontal cortex and circulating follicular helper T cells in neuromyelitis optica spectrum disorder patients with cognitive impairment

6. Effect of Biologics on the Need for Procedural Interventions, Systemic Medications, and Healthcare Utilization in Patients with Hidradenitis Suppurativa: Real-World Data from the UNITE Registry

7. Production profile and comparison analysis of main toxin components of Fusarium oxysporum f. sp. sesami isolates with different pathogenicity levels

8. Genome-wide analysis of the U-box E3 ubiquitin ligase family role in drought tolerance in sesame (Sesamum indicum L.)

9. Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer—A case series

10. Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo

11. Identification of Candidate Genes Regulating the Seed Coat Color Trait in Sesame (Sesamum indicum L.) Using an Integrated Approach of QTL Mapping and Transcriptome Analysis

12. Identification of the Mouse T Cell ADP-Ribosylome Uncovers ARTC2.2 Mediated Regulation of CD73 by ADP-Ribosylation

13. A high-density genetic map constructed using specific length amplified fragment (SLAF) sequencing and QTL mapping of seed-related traits in sesame (Sesamum indicum L.)

14. A P2rx7 Passenger Mutation Affects the Vitality and Function of T cells in Congenic Mice

15. Circulating Endothelial Cells as Promising Biomarkers in the Differential Diagnosis of Primary Angiitis of the Central Nervous System

16. Astrocytes and Microglia Are Resistant to NAD+-Mediated Cell Death Along the ARTC2/P2X7 Axis

17. Identification of a SiCL1 gene controlling leaf curling and capsule indehiscence in sesame via cross-population association mapping and genomic variants screening

18. Unconditional or Conditional Logistic Regression Model for Age-Matched Case–Control Data?

19. Genome-Wide Identification of Cyclic Nucleotide-Gated Ion Channel Gene Family in Wheat and Functional Analyses of TaCNGC14 and TaCNGC16

20. Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy

21. Fine mapping of wheat stripe rust resistance gene Yr26 based on collinearity of wheat with Brachypodium distachyon and rice.

22. TaAbc1, a member of Abc1-like family involved in hypersensitive response against the stripe rust fungal pathogen in wheat.

23. Functional characterization of calcineurin homologs PsCNA1/PsCNB1 in Puccinia striiformis f. sp. tritici using a host-induced RNAi system.

24. Molecular characterization of a Fus3/Kss1 type MAPK from Puccinia striiformis f. sp. tritici, PsMAPK1.

25. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*

26. Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

27. Supplementary Data from Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

28. Supplementary Table from Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

29. Data from Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

30. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A

31. Use of <scp>CYP3Ai</scp> and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the <scp>VIALE‐A</scp> study

32. Cost analysis of alpha blocker treatments for benign prostatic hyperplasia in Medicare beneficiaries

33. Real-world treatment patterns and clinical outcomes in Korean patients with AML ineligible for first-line intensive chemotherapy: A subanalysis of the CURRENT study, a non-interventional, retrospective chart review

34. Hydrogen Bond-Based Macrocyclic and Tripodal Neutral Ionophores for Highly Selective Polymeric Membrane Sulfate-Selective Electrodes

35. Effect of Levothyroxine on Kidney Function in Chronic Kidney Disease with Subclinical Hypothyroidism in US Veterans: A Retrospective Observational Cohort Study

37. Baseline patient‐reported outcomes from <scp>UNITE</scp> : an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

38. Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

39. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study

40. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

41. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

43. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

44. CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

45. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

46. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

47. Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

48. Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo.

49. Polymeric Membrane Fluoride-Selective Electrodes Using Lewis Acidic Organo-Antimony(V) Compounds as Ionophores

50. A P2rx7 passenger mutation affects the vitality and function of immune cells in P2X4ko and other transgenic mice

Catalog

Books, media, physical & digital resources